{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:31:30Z","timestamp":1784853090578,"version":"3.55.0"},"reference-count":37,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>New predictors of ischemic incidents are constantly sought since they raise the awareness of patients and their doctors of stroke occurrence. The goal was to verify whether Advanced Glycation End Products (AGEs), in particular AGE10, could be one of them. The AGE10 measurement was conducted using a non-commercial ELISA assay in the blood serum of neurological patients without cerebrovascular event (n = 24), those with transient brain attack (TIA) (n = 17), and severe ischemic stroke (n = 35). Twice as many of the people with TIA or severe stroke presented high AGE10 serum concentrations compared to the patients with other neurological conditions (\u03c72 = 8.2, p = 0.004; \u03c72 = 8.0, p = 0.005, respectively). The risk of ischemic incident was significantly risen in people with higher levels of AGE10 (OR = 6.5, CI95%: 1.7\u201324.8; OR = 4.7, CI95%: 1.5\u201314.5 for TIA and stroke subjects, respectively). We observed a positive correlation (r = 0.40) between high AGE10 levels and diabetes. Moreover, all the diabetic patients that had a high AGE10 content experienced either a severe ischemic stroke or TIA. The patients with high levels of AGE10 exhibited higher grades of disability assessed by the NIHSS scale (r = 0.35). AGE10 can be considered a new biomarker of ischemic stroke risk. Patients with diabetes presenting high AGE10 levels are particularly prone to the occurrence of cerebrovascular incidents.<\/jats:p>","DOI":"10.3390\/jcm13020443","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T07:25:07Z","timestamp":1705303507000},"page":"443","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced Glycation End-Products in Blood Serum\u2014Novel Ischemic Stroke Risk Factors? Implication for Diabetic Patients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4264-8174","authenticated-orcid":false,"given":"Aleksandra","family":"Kuzan","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Immunochemistry, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kozak-Syka\u0142a","sequence":"additional","affiliation":[{"name":"Neurology and Stroke Department, Independent Public Healthcare Centre, Jankowski Regional Hospital in Przeworsk, Szpitalna 16, 37-200 Przeworsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fiedorowicz","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Ka\u0142as","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Strz\u0105da\u0142a","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-6591","authenticated-orcid":false,"given":"Andrzej","family":"Gamian","sequence":"additional","affiliation":[{"name":"Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.annemergmed.2017.06.026","article-title":"Managing Patients With Transient Ischemic Attack","volume":"71","author":"Edlow","year":"2018","journal-title":"Ann. Emerg. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/STROKEAHA.118.021598","article-title":"HbA1c (Glycated Hemoglobin) Levels and Clinical Outcome Post-Mechanical Thrombectomy in Patients With Large Vessel Occlusion","volume":"50","author":"Choi","year":"2019","journal-title":"Stroke"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1001\/jama.284.22.2901","article-title":"Short-term prognosis after emergency department diagnosis of TIA","volume":"284","author":"Johnston","year":"2000","journal-title":"JAMA"},{"key":"ref_4","first-page":"457","article-title":"A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications","volume":"17","author":"Babel","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1021\/pr800858h","article-title":"A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease","volume":"8","author":"Zhang","year":"2009","journal-title":"J. Proteome Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/rp.56.1.1","article-title":"Protein glycation, diabetes, and aging","volume":"56","author":"Ulrich","year":"2001","journal-title":"Recent Prog. Horm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Khalid, M., Petroianu, G., and Adem, A. (2022). Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules, 12.","DOI":"10.3390\/biom12040542"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2337\/diab.43.5.676","article-title":"Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction","volume":"43","author":"Fu","year":"1994","journal-title":"Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0076-6879(99)09013-8","article-title":"Advanced glycation end products: Detection and reversal","volume":"309","author":"Kapurniotu","year":"1999","journal-title":"Methods Enzymol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"48905","DOI":"10.1074\/jbc.M205688200","article-title":"Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins","volume":"277","author":"Nagai","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Twarda-clapa, A., Olczak, A., Bia\u0142kowska, A.M., and Kozio\u0142kiewicz, M. (2022). Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells, 11.","DOI":"10.3390\/cells11081312"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/abbi.1997.0195","article-title":"Protein modification by methylglyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct","volume":"344","author":"Shipanova","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.1074\/jbc.M509436200","article-title":"The amphoterin (HMGB1)\/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo","volume":"281","author":"Riuzzi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1155175","DOI":"10.3389\/fnmol.2023.1155175","article-title":"AGE-RAGE axis culminates into multiple pathogenic processes: A central road to neurodegeneration","volume":"16","author":"Bhattacharya","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1055\/a-2047-3896","article-title":"AGE RAGE Pathways: Cardiovascular Disease and Oxidative Stress","volume":"73","author":"Sharma","year":"2023","journal-title":"Drug Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/da.22527","article-title":"Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study","volume":"34","author":"Pouwer","year":"2017","journal-title":"Depress. Anxiety"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ko, S.Y., Ko, H.A., Chu, K.H., Shieh, T.M., Chi, T.C., Chen, H.I., Chang, W.C., and Chang, S.S. (2015). The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer\u2019s Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143345"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.02.018","article-title":"Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective","volume":"317","author":"Li","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.mehy.2004.02.042","article-title":"TAGE (toxic AGEs) hypothesis in various chronic diseases","volume":"63","author":"Takeuchi","year":"2004","journal-title":"Med. Hypotheses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.2119\/molmed.2015.00067","article-title":"Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes","volume":"21","author":"Yamagishi","year":"2015","journal-title":"Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2841","DOI":"10.1002\/dmrr.2841","article-title":"Diabetic nephropathy in type 1 diabetes: A review of early natural history, pathogenesis, and diagnosis","volume":"33","author":"Chrousos","year":"2017","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14310\/horm.2002.11140","article-title":"Advanced glycation end products and diabetic complications: A general overview","volume":"4","author":"Peppa","year":"2005","journal-title":"Hormones"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semnephrol.2009.07.013","article-title":"Identifying advanced glycation end products as a major source of oxidants in aging: Implications for the management and\/or prevention of reduced renal function in elderly persons","volume":"29","author":"Vlassara","year":"2009","journal-title":"Semin. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wagner, K.H., Cameron-Smith, D., Wessner, B., and Franzke, B. (2016). Biomarkers of Aging: From Function to Molecular Biology. Nutrients, 8.","DOI":"10.3390\/nu8060338"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41371-020-0327-3","article-title":"The role of advanced glycation end products in vascular aging: Which parameter is the most suitable as a biomarker?","volume":"35","author":"Mayer","year":"2020","journal-title":"J. Hum. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1177\/03635465221090649","article-title":"Biochemical Markers of Aging (Advanced Glycation End Products) and Degeneration Are Increased in Type 3 Rotator Cuff Tendon Stumps With Increased Signal Intensity Changes on MRI","volume":"50","author":"Shinohara","year":"2022","journal-title":"Am. J. Sports Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41598-021-82585-7","article-title":"The melibiose-derived glycation product mimics a unique epitope present in human and animal tissues","volume":"11","author":"Staniszewska","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bronowicka-Szyde\u0142ko, A., Krzystek-Korpacka, M., Gacka, M., Pietkiewicz, J., Jakobsche-Policht, U., and Gamian, A. (2021). Association of Novel Advanced Glycation End-Product (AGE10) with Complications of Diabetes as Measured by Enzyme-Linked Immunosorbent Assay. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194499"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1533317506291075","article-title":"Analysis of Serum of Patients with Alzheimer\u2019s Disease for the Level of Advanced Glycation End Products","volume":"21","author":"Leszek","year":"2006","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Dement."},{"key":"ref_30","first-page":"71","article-title":"Advanced glycation end-products prepared in solution under high pressure contain epitopes distinct from those formed in the dry reaction at high temperature","volume":"53","author":"Staniszewska","year":"2005","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2017.02.030","article-title":"Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases","volume":"177","author":"Byun","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0976-7800.179166","article-title":"Risk factors of transient ischemic attack: An overview","volume":"7","author":"Khare","year":"2016","journal-title":"J. Mid-Life Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000444809","article-title":"Blood Brain Barrier Disruption in Diabetic Stroke Related to Unfavorable Outcome","volume":"42","author":"Yu","year":"2016","journal-title":"Cerebrovasc. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0000000000003200","article-title":"Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA","volume":"87","author":"Pan","year":"2016","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced Glycation End Products and Diabetic Complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mukherjee, S., Ray, S.K., Jadhav, A.A., and Wakode, S.L. (2023). Multi-level Analysis of HbA1c in Diagnosis and Prognosis of Diabetic Patients. Curr. Diabetes Rev., 20.","DOI":"10.2174\/0115733998262501231015051317"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhou, H., Pan, Y., Chen, W., Suo, Y., Yan, H., Meng, X., Zhao, X., Liu, L., Li, H., and Wang, Y. (2023). Smokers with Elevated Glycated Albumin Could Not Benefit from Dual Antiplatelet Therapy After Minor Stroke or Transient Ischemic Attack. Cerebrovasc. Dis., 1\u20138.","DOI":"10.1159\/000531349"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/2\/443\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:08Z","timestamp":1760103968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/2\/443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["jcm13020443"],"URL":"https:\/\/doi.org\/10.3390\/jcm13020443","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]}}}